openPR Logo
Press release

Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments

03-05-2020 04:13 PM CET | Health & Medicine

Press release from: Pharma Proff

Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails

Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates.

IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to be actively involved in pyrogenesis, cancer, rheumatoid arthritis, diabetes mellitus, and schizophrenia. The IL-6 inhibitors target the IL-6 receptors, thereby blocking the signaling pathway between receptors and mediators of inflammation that stimulate the accumulation of B cells.

Download sample copy of this report at: https://www.pharmaproff.com/request-sample/1222

According to the research, drugs being developed as IL-6 inhibitors, most of which are in clinical phases and can be expected to be given orally. It has been observed that the oral route of medications is convenient, available in delayed or rapid release formulation, less risk of systemic infections, and inexpensive in nature, and also provides improved patient's compliance.

Some of the companies involved in the development of IL-6 inhibitors include F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals Inc., Sanofi-aventis Groupe, Janssen Global Services LLC, Novimmune SA, UCB Pharma.

Browse full report at: https://www.pharmaproff.com/report/interleukin-6-inhibitors-therapeutics-pipeline

IL-6 Inhibitors Pipeline Analysis
o By Phase
o By Molecule Type
o By Route of Administration
o By Company

Contact:
Pharma Proff
US/Canada Toll-Free : +1-888-778-7886
International : +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

About Pharma Proff

Pharma Proff, a brainchild of Prescient & Strategic (P&S) Intelligence Private Limited, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments here

News-ID: 1956490 • Views: 4504

More Releases from Pharma Proff

Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: https://www.pharmaproff.com/request-sample/1189 Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances
Hepatorenal Syndrome Therapeutics Pipeline Analysis 2018, Clinical Trials & Resu …
Hepatorenal syndrome (HRS) is a reversible functional renal impairment, that occurs in patients with advanced liver cirrhosis or those with fulminant hepatic failure. It is characterized by a marked reduction in glomerular filtration rate and renal plasma flow, in the absence of other causes of renal failure. Download the sample report at: https://www.pharmaproff.com/request-sample/1030 The symptoms of hepatorenal syndrome are fatigue, abdominal pain, malaise, ascites, jaundice, splenomegaly, and hepatomegaly. There are two

All 5 Releases


More Releases for Inhibitors

Global Protein Kinase Inhibitors Market Research Report
This report studies the global Protein Kinase Inhibitors market status and forecast, categorizes the global Protein Kinase Inhibitors market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Bayer Astra Zeneca Roche Teva Apotex Novartis Glaxosmithkline Pfizer Geographically, this report studies the top
PARP Inhibitors Market Trends and Segments
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These
AKT Inhibitors - Pipeline Insights 2017
The “AKT Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of AKT drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential AKT inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent, and USFDA and
AKT Inhibitors - Pipeline Insights 2017
The “AKT Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of AKT drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential AKT inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent, and USFDA and
CDK Inhibitors Therapeutics Pipeline Analysis 2017
The study analyzed that the CDK inhibitors therapeutics pipeline comprises approximately 24 drug candidates in different stages of development. CDKs are the catalytic subunits of serine or threonine protein kinases that regulate the checkpoints in the cell cycle to control the proliferative capacity of cancerous cells. These proteins form cyclin-CDK complex which gets activated after phosphorylation, leading to cell proliferation. Explore Report at: www.psmarketresearch.com/market-analysis/cdk-inhibitors-therapeutics-pipeline-analysis USFDA granted Breakthrough Therapy Designation to a drug
Global Histone Deacetylase Inhibitors Market
Histone deacetylase (HDAC) is enzymes, which inhibits histone deacetylase by removing scetyl group from n-acetyl lysine amino acid. Histone deacetylase inhibitors are emerging as potential application in diagnosis, treatment and prognosis of cancer. It is also considered as a treatment option for hematological malignancies and plays important role in epigenetic or non-epigenetic regulation. The histone deacetylase inhibitors accumulates acetylated nuclear histone in tumors and normal tissues. Thus, the inhabitation results